PAX2 promotes epithelial ovarian cancer progression involving fatty acid metabolic reprogramming

Feng,Yan; Tang,Yong; Mao,Yannan; Liu,Yingzhao; Yao,Desheng; Yang,Linkai; Garson,Kenneth; Vanderhyden,Barbara  C.; Wang,Qi

doi:10.3892/ijo.2020.4958

PAX2 promotes epithelial ovarian cancer progression involving fatty acid metabolic reprogramming

Authors:
- Yan Feng
- Yong Tang
- Yannan Mao
- Yingzhao Liu
- Desheng Yao
- Linkai Yang
- Kenneth Garson
- Barbara C. Vanderhyden
- Qi Wang
View Affiliations

Affiliations: Research Department, Guangxi Medical University Cancer Hospital, Nanning, Guangxi Zhuang Autonomous Region 530021, P.R. China, Department of Urology, Wuming Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region 530199, P.R. China, Centre for Cancer Therapeutics, Ottawa Hospital Research Institute, Ottawa, ON K1H 8L6, Canada
Published online on: January 10, 2020 https://doi.org/10.3892/ijo.2020.4958
Pages: 697-708
Copyright: © Feng et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Ovarian cancer is the fifth most common type of cancer afflicting women and frequently presents at a late stage with a poor prognosis. While paired box 2 (PAX2) expression is frequently lost in high‑grade serous ovarian cancer, it is expressed in a subset of ovarian tumors and may play a role in tumorigenesis. This study investigated the expression of PAX2 in ovarian cancer. The expression of PAX2 in a murine allograft model of ovarian cancer, the RM model, led to a more rapidly growing cell line both in vitro and in vivo. This finding was in accordance with the shorter progression‑free survival observed in patients with a higher PAX2 expression, as determined in this study cohort by immunohistochemistry. iTRAQ‑based proteomic profiling revealed that proteins involved in fatty acid metabolism and oxidative phosphorylation were found to be upregulated in RM tumors expressing PAX2. The expression of two key fatty acid metabolic genes was also found to be upregulated in PAX2‑expressing human ovarian cancer samples. The analysis of existing datasets also indicated that a high expression of key enzymes in fatty acid metabolism was associated with a shorter progression‑free survival time in patients with serous ovarian cancer. Thus, on the whole, the findings of this study indicate that PAX2 may promote ovarian cancer progression, involving fatty acid metabolic reprograming.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer Statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
2	Perets R, Wyant GA, Muto KW, Bijron JG, Poole BB, Chin KT, Chen JY, Ohman AW, Stepule CD, Kwak S, et al: Transformation of the fallopian tube secretory epithelium leads to high-grade serous ovarian cancer in brca; tp53; pten models. Cancer Cell. 24:751–765. 2013. View Article : Google Scholar : PubMed/NCBI
3	Wang M, Ma H, Pan Y, Xiao W, Li J, Yu J and He J: PAX2 and PAX8 reliably distinguishes ovarian serous tumors from mucinous tumors. Appl Immunohistochem Mol Morphol. 23:280–287. 2015. View Article : Google Scholar
4	Song H, Kwan SY, Izaguirre DI, Zu Z, Tsang YT, Tung CS, King ER, Mok SC, Gershenson DM and Wong KK: PAX2 expression in ovarian cancer. Int J Mol Sci. 14:6090–6105. 2013. View Article : Google Scholar : PubMed/NCBI
5	Alhujaily EM, Tang Y, Yao D, Carmona E, Garson K and Vanderhyden BC: Divergent roles of PAX2 in the Etiology and Progression of Ovarian Cancer. Cancer Prev Res. 8:1163–1173. 2015. View Article : Google Scholar
6	Maulbecker CC and Gruss P: The oncogenic potential of Pax genes. EMBO J. 12:2361–2367. 1993. View Article : Google Scholar : PubMed/NCBI
7	Muratovska A, Zhou C, He S, Goodyer P and Eccles MR: Paired-Box genes are frequently expressed in cancer and often required for cancer cell survival. Oncogene. 22:7989–7997. 2003. View Article : Google Scholar : PubMed/NCBI
8	Chen EY, Mehra K, Mehrad M, Ning G, Miron A, Mutter GL, Monte N, Quade BJ, McKeon FD, Yassin Y, et al: Secretory cell outgrowth, PAX2 and serous carcinogenesis in the Fallopian tube. J Pathol. 222:110–116. 2010.PubMed/NCBI
9	Robson EJ, He SJ and Eccles MR: A PANorama of PAX genes in cancer and development. Nat Rev Cancer. 6:52–62. 2006. View Article : Google Scholar : PubMed/NCBI
10	Zhang HS, Yan XB, Li XB, Fan L, Zhang YF, Wu GH, Li M and Fang J: PAX2 Protein induces expression of cyclin D1 through activating AP-1 protein and promotes proliferation of colon cancer Cells. J Biol Chem. 287:44164–44172. 2012. View Article : Google Scholar : PubMed/NCBI
11	Zhang LP, Shi XY, Zhao CY, Liu YZ and Cheng P: RNA interference of pax2 inhibits growth of transplanted human endometrial cancer cells in nude mice. Chin J Cancer. 30:400–406. 2011. View Article : Google Scholar : PubMed/NCBI
12	Hueber PA, Iglesias D, Chu LL, Eccles M and Goodyer P: In vivo validation of PAX2 as a target for renal cancer therapy. Cancer Lett. 265:148–155. 2008. View Article : Google Scholar : PubMed/NCBI
13	Penzvalto Z, Lanczky A, Lenart J, Meggyesházi N, Krenács T, Szoboszlai N, Denkert C, Pete I and Győrffy B: MEK1 is associated with carboplatin resistance and is a prognostic biomarker in epithelial ovarian cancer. BMC Cancer. 14:837. 2014. View Article : Google Scholar : PubMed/NCBI
14	Gyorffy B, Lanczky A and Szallasi Z: Implementing an online tool for genome-wide validation of survival-associated biomarkers in ovarian-cancer using microarray data from 1287 patients. Endocr-Relat Cancer. 19:197–208. 2012. View Article : Google Scholar : PubMed/NCBI
15	Marín-García J: Mechanisms of bioenergy production in mitochondria. Springer; Boston, MA: pp. 99–121. 2013
16	Nieman KM, Kenny HA, Penicka CV, Ladanyi A, Buell-Gutbrod R, Zillhardt MR, Romero IL, Carey MS, Mills GB, Hotamisligil GS, et al: Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat Med. 17:1498–1503. 2011. View Article : Google Scholar : PubMed/NCBI
17	Pavlova NN and Thompson CB: The emerging hallmarks of cancer metabolism. Cell Metab. 23:27–47. 2016. View Article : Google Scholar : PubMed/NCBI
18	Kellenberger LD, Bruin JE, Greenaway J, Campbell NE, Moorehead RA, Holloway AC and Petrik J: The role of dysregulated glucose metabolism in epithelial ovarian cancer. J Oncol. 2010:5143102010. View Article : Google Scholar : PubMed/NCBI
19	Lim HY, Ho QS, Low J, Choolani M and Wong KP: Respiratory competent mitochondria in human ovarian and peritoneal cancer. Mitochondrion. 11:437–443. 2011. View Article : Google Scholar : PubMed/NCBI
20	Hanahan D and Weinberg RA: Hallmarks of cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
21	Chivukula M, Dabbs DJ, O'Connor S and Bhargava R: PAX 2: A novel Mullerian marker for serous papillary carcinomas to differentiate from micropapillary breast carcinoma. Int J Gynecol Pathol. 28:570–578. 2009. View Article : Google Scholar : PubMed/NCBI
22	Priebe A, Tan L, Wahl H, Kueck A, He G, Kwok R, Opipari A and Liu JR: Glucose deprivation activates AMPK and induces cell death through modulation of Akt in ovarian cancer cells. Gynecol Oncol. 122:389–395. 2011. View Article : Google Scholar : PubMed/NCBI
23	Anderson AS, Roberts PC, Frisard MI, McMillan RP, Brown TJ, Lawless MH, Hulver MW and Schmelz EM: Metabolic changes during ovarian cancer progression as targets for sphingosine treatment. Exp Cell Res. 319:1431–1442. 2013. View Article : Google Scholar : PubMed/NCBI
24	Fong MY, McDunn J and Kakar SS: Identification of metabolites in the normal ovary and their transformation in primary and metastatic ovarian cancer. PLoS One. 6:e199632011. View Article : Google Scholar : PubMed/NCBI
25	Ke C, Hou Y, Zhang H, Fan L, Ge T, Guo B, Zhang F, Yang K, Wang J, Lou G and Li K: Large-scale profiling of metabolic dysregulation in ovarian cancer. Int J Cancer. 136:516–526. 2015.
26	Montopoli M, Bellanda M, Lonardoni F, Ragazzi E, Dorigo P, Froldi G, Mammi S and Caparrotta L: 'Metabolic reprogramming' in ovarian cancer cells resistant to cisplatin. Curr Cancer Drug Targets. 11:226–235. 2011. View Article : Google Scholar
27	Bauerschlag DO, Maass N, Leonhardt P, Verburg FA, Pecks U, Zeppernick F, Morgenroth A, Mottaghy FM, Tolba R, Meinhold-Heerlein I and Bräutigam K: Fatty acid synthase over-expression: Target for therapy and reversal of chemoresistance in ovarian cancer. J Transl Med. 13:146. 2015. View Article : Google Scholar
28	Pasto A, Bellio C, Pilotto G, Ciminale V, Silic-Benussi M, Guzzo G, Rasola A, Frasson C, Nardo G, Zulato E, et al: Cancer stem cells from epithelial ovarian cancer patients privilege oxidative phosphorylation, and resist glucose deprivation. Oncotarget. 5:4305–4319. 2014. View Article : Google Scholar : PubMed/NCBI
29	Raspollini MR, Amunni G, Villanucci A, Boddi V and Taddei GL: Increased cyclooxygenase-2 (COX-2) and P-glycoprotein-170 (MDR1) expression is associated with chemotherapy resistance and poor prognosis. Analysis in ovarian carcinoma patients with low and high survival. Int J Gynecol Cancer. 15:255–260. 2005. View Article : Google Scholar : PubMed/NCBI
30	Ferrandina G, Lauriola L, Zannoni GF, Fagotti A, Fanfani F, Legge F, Maggiano N, Gessi M, Mancuso S, Ranelletti FO and Scambia G: Increased cyclooxygenase-2 (COX-2) expression is associated with chemotherapy resistance and outcome in ovarian cancer patients. Ann Oncol. 13:1205–1211. 2002. View Article : Google Scholar : PubMed/NCBI
31	Chkourko Gusky H, Macdougald OA and Podgorski I: Omentum and bone marrow: How adipocyte-rich organs create tumour microenvironments conducive for metastatic progression. Obes Rev. 17:1015–1029. 2016. View Article : Google Scholar : PubMed/NCBI
32	Fan S, Wang Y, Zhang Z, Lu J, Wu Z, Shan Q, Sun C, Wu D, Li M, Sheng N, et al: High expression of glutamate-ammonia ligase is associated with unfavorable prognosis in patients with ovarian cancer. J Cell Biochem. 119:6008–6015. 2018. View Article : Google Scholar : PubMed/NCBI
33	Shim GS, Manandhar S, Shin DH, Kim TH and Kwak MK: Acquisition of doxorubicin resistance in ovarian carcinoma cells accompanies activation of the NRF2 pathway. Free radical biology & medicine. 47:1619–1631. 2009. View Article : Google Scholar
34	Yuan L, Sheng X, Willson AK, Roque DR, Stine JE, Guo H, Jones HM, Zhou C and Bae-Jump VL: Glutamine promotes ovarian cancer cell proliferation through the mTOR/S6 pathway. Endocr Relat Cancer. 22:577–591. 2015. View Article : Google Scholar : PubMed/NCBI
35	Papaevangelou E, Almeida GS, Box C, deSouza NM and Chung YL: The effect of FASN inhibition on the growth and metabolism of a cisplatin-resistant ovarian carcinoma model. Int J Cancer. 143:992–1002. 2018. View Article : Google Scholar : PubMed/NCBI
36	Kobayashi Y, Kashima H, Wu RC, Jung JG, Kuan JC, Gu J, Xuan J, Sokoll L, Visvanathan K, Shih IeM and Wang TL: Mevalonate pathway antagonist suppresses formation of serous tubal intraepithelial carcinoma and ovarian carcinoma in mouse models. Clin Cancer Res. 21:4652–4662. 2015. View Article : Google Scholar : PubMed/NCBI
37	Matassa DS, Amoroso MR, Lu H, Avolio R, Arzeni D, Procaccini C, Faicchia D, Maddalena F, Simeon V, Agliarulo I, et al: Oxidative metabolism drives inflammation-induced platinum resistance in human ovarian cancer. Cell Death Differ. 23:1542–1554. 2016. View Article : Google Scholar : PubMed/NCBI
38	Harjes U, Bridges E, Gharpure KM, Roxanis I, Sheldon H, Miranda F, Mangala LS, Pradeep S, Lopez-Berestein G, Ahmed A, et al: Antiangiogenic and tumour inhibitory effects of downregulating tumour endothelial FABP4. Oncogene. 36:912–921. 2017. View Article : Google Scholar :